Aldesleukin Terminated Phase 2 Trials for Melanoma / Skin Cancers Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02111863Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
NCT00505635Biochemotherapy With Temozolomide for Metastatic Melanoma
NCT00509496Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
NCT00706992Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients